Alex Ossola

They're currently in trials, and if the drugs work, the companies could be on the verge of the next big market for heart drugs.

It's valued at as much as $25 billion a year.

Journal reporter Xavier Martinez joins me now with more.

Xavier, lipoprotein A, or LPA, has been difficult to treat for a long time.

Diet and exercise don't really help because it's genetic.

And other heart drugs like statins can actually raise LPA.

What's different about these new drugs?

You mentioned that these drugs are in trials right now.

How promising are they looking and what still needs to happen before they can go in front of the FDA for approval?

Just to be clear on one point here, we know that higher levels of LPA are linked to heart disease.

But it's not totally clear yet that a drug that then lowers those levels of LPA will help cut the risk of heart disease.

Is that right?

That was WSJ reporter Xavier Martinez.

Thanks, Xavier.

Lululemon is making peace with its founder, Chip Wilson.

Wilson is a big shareholder, owning 8.7 percent of Lululemon's shares.

And he's criticized the leggings company for years, arguing that it's no longer cool and has given up its lead to newer rivals.

For example, last October on CNBC's Squawk Box, he said that the board was too focused on hitting Wall Street's numbers.

In December, he launched a proxy fight seeking to overhaul the company's board.

Now, Lululemon and Wilson have reached a deal.